Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathwayNadège Presneau(University College London), Adrienne M. Flanagan(Institute of Structural and Molecular Biology)British Journal of CancerApril 28, 200910.1038/sj.bjc.6605019Cited by 118SaveCiteExport RISWatch citationsRelated PapersAnalysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas|Modern Pathology|2009|38